Citadel Advisors
OTLK icon

Citadel Advisors’s Outlook Therapeutics OTLK Stock Holding History

Citadel Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,692
Closed -$15.2K – 15290
2024
Q4 		$16.4K Buy
+8,692
New +$35.8K ﹤0.01% 13305
2023
Q4 		– Sell
-676
Closed -$2.99K – 14960
2023
Q3 		$2.99K Buy
+676
New +$15K ﹤0.01% 13649
2023
Q2 		– Sell
-4,533
Closed -$98.8K – 14981
2023
Q1 		$98.8K Buy
4,533
+2,472
+120% +$55.3K ﹤0.01% 11281
2022
Q4 		$44.5K Buy
2,061
+421
+26% +$9.16K ﹤0.01% 12274
2022
Q3 		$40K Buy
1,640
+1,112
+211% +$25.9K ﹤0.01% 11762
2022
Q2 		$11K Sell
528
-3,196
-86% -$91.9K ﹤0.01% 12567
2022
Q1 		$133K Sell
3,724
-165
-4% -$5.15K ﹤0.01% 11983
2021
Q4 		$106K Sell
3,889
-2,336
-38% -$83.3K ﹤0.01% 12663
2021
Q3 		$270K Buy
6,225
+2,408
+63% +$116K ﹤0.01% 11294
2021
Q2 		$191K Sell
3,817
-5,001
-57% -$232K ﹤0.01% 12213
2021
Q1 		$397K Buy
8,818
+4,447
+102% +$170K ﹤0.01% 10192
2020
Q4 		$114K Buy
+4,371
New +$91.3K ﹤0.01% 10141
2018
Q1 		– Sell
-154
Closed -$32K – 8636
2017
Q4 		$32K Buy
+154
New +$31.9K ﹤0.01% 7752

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Citadel Advisors's OTLK Position: Q1 2025 in Review

Citadel Advisors sold out of Outlook Therapeutics (OTLK) in Q1 2025, closing a stake of 8,692 shares — an estimated $15.2K sold.

Citadel Advisors first reported a position in OTLK in Q4 2017 and held it in 13 quarters. The position peaked at $397K in Q1 2021. 63 funds tracked by Wall St. Rank hold OTLK as of Q1 2025.

  • Citadel Advisors reported no remaining Outlook Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 8,692 Outlook Therapeutics shares in Q1 2025, an estimated $15.2K.
  • Citadel Advisors first reported a position in Outlook Therapeutics in Q4 2017 and held it in 13 quarters.
  • Citadel Advisors's Outlook Therapeutics position peaked at $397K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.